Low Ki-67 proliferation index is an indicator of poor prognosis in gastric cancer

Journal of Surgical Oncology

Volumn 102, Issue 3, 2010, Pages 201-206

  Lee, Hee Eun ^a   Kim, Min A ^a   Lee, Byung Lan ^a   Kim, Woo Ho ^a  

^a Seoul National University   (South Korea)

Author keywords

Immunohistochemistry; Stomach neoplasms; Survival analysis; Tissue array analysis

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; STOMACH NEOPLASMS;

EID: 77956368279     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21583     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J, et al.: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Hejna M, Wohrer S, Schmidinger M, et al.: Postoperative chemotherapy for gastric cancer. Oncologist 2006;11:136-145.
3. Hartgrink HH, van de Velde CJ: Status of extended lymph node dissection: Locoregional control is the only way to survive gastric cancer. J Surg Oncol 2005;90:153-165.
4. Novotny AR, Schuhmacher C, Busch R, et al.: Predicting individual survival after gastric cancer resection: Validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg 2006;243:74-81. (Pubitemid 43054057)
5. Fenoglio-Preiser C, Carneiro F, Correa P, et al.: Gastric carcinoma. In: Hamilton SR, Aaltonen LA, editors. World Health Organization classification of tumors; pathology and genetics of tumors of the digestive system. Lyon: IARC Press; 2000. pp. 37-52.
6. Lewin KJ, Appleman HD: Carcinoma of the stomach. In: Rosai J, editor. Atlas of Tumor pathology; tumors of the esophagus and stomach. Washington, DC: Armed Forces Institute of Pathology; 1996. pp. 245-330.
7. Scholzen T, Gerdes J: The Ki-67 protein: From the known and the unknown. J Cell Physiol 2000;182:311-322.
8. Cattoretti G, Becker MH, Key G, et al.: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363. (Pubitemid 23013251)
9. Aaltomaa S, Lipponen P, Vesalainen S, et al.: Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 1997;32:410-415. (Pubitemid 27501037)
10. Borre M, Bentzen SM, Nerstrom B, et al.: Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol 1998;159:1609-1614. (Pubitemid 29117351)
11. Keshgegian AA, Johnston E, Cnaan A: Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 1998;110:443-449. (Pubitemid 28443436)
12. Bai XZ, Masters JR, O'Donoghue N, et al.: Prognostic markers in clinically localised prostate cancer. Int J Oncol 1999;14:785-791.
13. Colozza M, Azambuja E, Cardoso F, et al.: Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now? Ann Oncol 2005;16:1723-1739.
14. McLoughlin J, Foster CS, Price P, et al.: Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Br J Urol 1993;72:92-97. (Pubitemid 23227442)
15. Sadi MV, Barrack ER: Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer 1991;67:3065-3071.
16. Uzoaru I, Rubenstein M, Mirochnik Y, et al.: An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer. J Surg Oncol 1998;67:33-37. (Pubitemid 28074129)
17. Weikel W, Beck T, Mitze M, et al.: Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 1991;18:149-154.
18. Iacopetta B, Grieu F, Powell B, et al.: Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res 1998;4:1597-1602. (Pubitemid 28304719)
19. de Manzoni G, Verlato G, Tomezzoli A, et al.: Study on Ki-67 immunoreactivity as a prognostic indicator in patients with advanced gastric cancer. Jpn J Clin Oncol 1998;28:534-537.
20. Setala L, Kosma VM, Lipponen P, et al.: Clinical relevance of p53 index and expression of proliferating cell nuclear antigen and Ki-67 in gastric cancer. J Cancer Res Clin Oncol 1998;124:497-502.
21. Kikuyama S, Kubota T, Shimizu K, et al.: Ki-67 antigen expression in relation to clinicopathological variables and prognosis in gastric cancer. Oncol Rep 1998;5:867-870. (Pubitemid 28270683)
22. Victorzon M, Roberts PJ, Haglund C, et al.: Ki-67, ploidy and S-phase fraction as prognostic factors in gastric cancer. Anticancer Res 1997;17:2923-2926. (Pubitemid 27436085)
23. Muller W, Schneiders A, Meier S, et al.: Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Br J Cancer 1996;74:759-765. (Pubitemid 26300768)
24. Liu XP, Tsushimi K, Tsushimi M, et al.: Expression of p21(WAF1/CIP1) and p53 proteins in gastric carcinoma: Its relationships with cell proliferation activity and prognosis. Cancer Lett 2001;170:183-189. (Pubitemid 32709919)
25. Goishi H, Tanaka S, Haruma K, et al.: Predictive value of cathepsin D and Ki-67 expression at the deepest penetration site for lymph node metastases in gastric cancer. Oncol Rep 2000;7:713-718.
26. Kanai T, Konno H, Maruyama K, et al.: p53 overexpression and proliferative activity do not correlate with lymph node metastasis in early gastric cancer. Eur Surg Res 1997;29:35-41. (Pubitemid 27033725)
27. Pan W, Ishii H, Ebihara Y, et al.: Prognostic use of growth characteristics of early gastric cancer and expression patterns of apoptotic, cell proliferation, and cell adhesion proteins. J Surg Oncol 2003;82:104-110. (Pubitemid 36164445)
28. Ramires M, David L, Leitao D, et al.: Ki67 labelling index in gastric carcinomas. An immunohistochemical study using double staining for the evaluation of the proliferative activity of diffuse-type carcinomas. J Pathol 1997;182:62-67. (Pubitemid 27240450)
29. Schipper DL, Wagenmans MJ, Peters WH, et al.: Significance of cell proliferation measurement in gastric cancer. Eur J Cancer 1998;34:781-790. (Pubitemid 28248486)
30. Lee HS, Lee HK, Kim HS, et al.: MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: Their roles as prognostic indicators. Cancer 2001;92:1427-1434.
31. Kim MA, Lee HS, Lee HE, et al.: Prognostic importance of epithelial-mesenchymal transition-related protein expression in gastric carcinoma. Histopathology 2009;54:442-451.
32. Allegra CJ, Paik S, Colangelo LH, et al.: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003;21:241-250. (Pubitemid 46606152)
33. Garrity MM, Burgart LJ, Mahoney MR, et al.: Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: A North Central Cancer Treatment Group Study. J Clin Oncol 2004;22:1572-1582.
34. Palmqvist R, Sellberg P, Oberg A, et al.: Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers. Br J Cancer 1999;79:577-581. (Pubitemid 29046239)
35. Robbins SL, Cotran RS: Neoplasia. In: Kumar V, Abbas AK, Fausto N, editors. Robbins and Cotran pathologic basis of disease. Philadelphia: Elsevier Saunders; 2005. p. 319.
36. Gao CF, Xie Q, Su YL, et al.: Proliferation and invasion: Plasticity in tumor cells. Proc Natl Acad Sci USA 2005;102:10528-10533. (Pubitemid 41061588)
37. Ewton DZ, Kansra S, Lim S, et al.: Insulin-like growth factor-I has a biphasic effect on colon carcinoma cells through transient inactivation of forkhead1, initially mitogenic, then mediating growth arrest and differentiation. Int J Cancer 2002;98:665-673. (Pubitemid 34225616)
38. Takano Y, Saegusa M, Ikenaga M, et al.: Apoptosis of colon cancer: Comparison with Ki-67 proliferative activity and expression of p53. J Cancer Res Clin Oncol 1996;122:166-170. (Pubitemid 26079090)